New and emerging targeted therapies for advanced breast cancer

KH Lau, AM Tan, Y Shi - International journal of molecular sciences, 2022 - mdpi.com
In the United States, breast cancer is among the most frequently diagnosed cancers in
women. Breast cancer is classified into four major subtypes: human epidermal growth factor …

Sodium alginate based drug delivery in management of breast cancer

MAJ Shaikh, KS Alharbi, WH Almalki, SS Imam… - Carbohydrate …, 2022 - Elsevier
Among women, breast cancer (B· C.) is a common form of cancer that can strike either
developed or develo** countries. In addition to pregnancy-related variables, hormone …

Molecular perspective on targeted therapy in breast cancer: a review of current status

B Demir Cetinkaya, C Biray Avci - Medical Oncology, 2022 - Springer
Breast cancer is categorized at the molecular level according to the status of certain
hormone and growth factor receptors, and this classification forms the basis of current …

Molecular pathways and therapeutic targets linked to triple-negative breast cancer (TNBC)

M Mustafa, K Abbas, M Alam, W Ahmad… - Molecular and cellular …, 2024 - Springer
Cancer is a group of diseases characterized by uncontrolled cellular growth, abnormal
morphology, and altered proliferation. Cancerous cells lose their ability to act as anchors …

Cancer therapy and treatments during COVID-19 era

SM Akula, SL Abrams, LS Steelman, S Candido… - Advances in biological …, 2020 - Elsevier
The COVID-19 pandemic has put a serious strain on health treatments as well at the
economies of many nations. Unfortunately, there is not currently available vaccine for SARS …

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study

JK Litton, JT Beck, JM Jones, J Andersen… - The …, 2023 - academic.oup.com
Background The undetermined efficacy of the current standard-of-care neoadjuvant
treatment, anthracycline/platinum-based chemotherapy, in patients with early-stage triple …

Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests

TG Meijer, L Nguyen, A Van Hoeck, AM Sieuwerts… - Oncogene, 2022 - nature.com
Germline BRCA1/2 mutation status is predictive for response to Poly-[ADP-Ribose]-
Polymerase (PARP) inhibitors in breast cancer (BC) patients. However, non-germline …

[HTML][HTML] Trailblazing perspectives on targeting breast cancer stem cells

J Li, D Qi, TC Hsieh, JH Huang, JM Wu, E Wu - Pharmacology & …, 2021 - Elsevier
Breast cancer (BCa) is one of the most prevalent malignant tumors affecting women's health
worldwide. The recurrence and metastasis of BCa have made it a long-standing challenge …

Risk of pneumonitis in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS …

Z Ma, X Sun, Z Zhao, W Lu, Q Guo, S Wang, J You… - Gynecologic …, 2021 - Elsevier
Abstract Objective/Background We aimed to evaluate the risk of PARP inhibitors (PARPis)
causing pneumonitis in randomized controlled trials (RCTs) and in the real-world practice …

[HTML][HTML] Diabetes-associated breast cancer is molecularly distinct and shows a DNA damage repair deficiency

G Panigrahi, J Candia, TH Dorsey, W Tang, Y Ohara… - JCI insight, 2023 - ncbi.nlm.nih.gov
Diabetes commonly affects patients with cancer. We investigated the influence of diabetes
on breast cancer biology using a 3-pronged approach that included analysis of orthotopic …